Psychiatric disorder risperidone

A role for the 5-HT7 receptor in the regulation of circadian rhythms has been implicated. As discussed above, 5-HT has been known for some time to induce phase shifts in behavioral circadian rhythms and modulate neuronal activity in the suprachiasmatic nucleus, the likely site of the mammalian circadian clock. The pharmacological characteristics of the effect of 5-HT on circadian rhythms are consistent with 5-HT7 receptor. Moreover, mRNA for the 5-HT7 receptor is found in the suprachiasmatic nucleus. There is also increasing evidence that the 5-HT7 receptor may play a role in psychiatric disorders. The regional distribution of 5-HT7 receptors in brain includes limbic areas and cortex. Atypical antipsychotics, such as clozapine and risperidone, and some antidepressants display high affinity for this receptor. In the periphery, 5-HT7 receptors havebeenshown to mediate relaxation of vascular smooth muscle. 

There have been numerous trials of use of the atypical antipsychotics in patients with developmental disabilities, but most of these trials were uncontrolled open-labeled studies or case reports (Aman and Madrid, 1999). Findings were reported for 86 adults and 1 child with prominent self-injury. The reports of adults assessed clozapine (1 report) and risperidone (4 reports). Improvement was observed for a majority of participants in all of these trials. The patients presented with a multitude of conditions, ranging from nonspecific MR and associated behavior problems, to pervasive developmental disorders (including autism), to various psychiatric disorders, including schizophrenia and manic disorder. Self-injury appeared to respond to treatment regardless of concomitant condition. In the only clozapine report with a child (who had autistic disorder), a mean dose of 283 mg/day caused a transient reduction in self-injury. 

A 75-year-old white man, without a history of psychiatric disorders, took cortisone 50 mg/day for 6 weeks for pulmonary fibrosis and developed severe obsessive-compulsive behavior without affective or psychotic symptoms. He was given risperidone without any beneficial effect. The dose of cortisone was tapered over 18 days. An MRI scan showed no signs of organic brain disease and an electroencephalogram was normal. His symptoms improved 16 days after withdrawal and resolved completely after 24 days. Risperidone was withdrawn without recurrence. 

A 23-year-old woman with ulcerative colitis and no previous psychiatric disorders developed emotional lability, euphoria, persecutory delusions, irritability, and increased motor and verbal activity 3 weeks after starting to take betamethasone 4 mg/day. She improved within a few weeks with bromperidol 3 mg/ day. After 10 months she became unable to speak and eat, was mute, depressive, and sorrowful, and responded poorly to questions. There were no neurological signs and betamethasone had been withdrawn 10 months before. She was treated with intravenous clomipramine 25 mg/day and became able to speak. Intravenous clomipramine caused dizziness due to hypotension, and amoxapine 150 mg/day was substituted after 6 days. All of her symptoms improved within 10 days. Risperidone was added for mood lability and mild persecutory ideation. 

Alcohol Health Res World 22 122-123, 1998 Solhkhah R, Finkel J, Hird S Possible risperidone-induced visual hallucinations. J Am Acad Child Adolesc Psychiatry 39 1074-1073, 2000 Solhkhah R, Wilens TE, Prince JB, et al Bupropion sustained release for substance abuse, ADHD, and mood disorders in adolescents (NR31), in New Research Absrracts, Annual Meeting of the American Psychiatric Associarion. Washington, DC, American Psychiatric Associarion, 2001... 

Patel, N. C., Crismon, M. L., Shafer, A., De Leon, A., Lopez, M. et al. (2006). Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. Soc. Psychiatry. Psychiatr. Epidemiol., 41, 341-6. 

Sachs G, Bowden C, Chou J, et al. Risperidone versus placebo as combination therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder focus on efficacy. Presented at the American Psychiatric Association Annual Meeting, Chicago, May 13-18, 2000. 

Madhusoodanan S, Brenner R, Cohen Cl. Risperidone for elderly patients with schizophrenia or schizoaffective disorder. Psychiatr Ann 2000 30 175-180. 

A 36-year-old woman with a history of psychiatric illness, including paranoid disorder, depression with panic episodes, and stress disorder, was found dead in bed. Caffeine, risperidone, and zolpidem were found in her urine. 

Psychiatric The incidence of suicide-related events in patients with schizophrenia or bipolar disorder taking aripiprazole has been studied using administrative data from three US sources [65 "]. Suicide attempts and death by suicide were assessed in patients aged at least 18 years. Among 20489 antipsychotic drug users (8985 patient-years), unadjusted suicide event rates per 1000 patient-years were 21 for aripiprazole 24 for olanzapine 32 for quetiapine 20 for risperidone and 49 for ziprasidone. Compared with current users of the other antipsychotic... 

Peitl MV, Peitl V, Grahovac T, Pavlovic E. Galactorrhea—side effect of risperidone in combination with Depakine Chrono in a patient with bipolar disorder. Psychiatr Danub 2010 22 125-7. 

MacMillan CM, Withney JE, Kornddrfer SR, Tilley CA, Mrakotsky C, Gonzalez-Heydrich JM. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J Psychiatr Pract 2008 14(3) 160-9. 

---